oral glp-1 medications approved FDA Approves Semaglutide: First Weight Loss Pill Oral GLP-1-Based Therapeutics in the

In a second treatment scenario, we assume that the diabetes prevention results from the clinical trial persist for the remainder of patients lives

Additionally, GLP-1 agonists slow gastric emptying, which prolongs the sensation of fullness after eating

Evidence from pre/post, quasi-experimental, and some randomized interventions supports the benefits of FIM for food security, nutrition security, diet quality, blood glucose control, hypertension, disease self-management, self-perceived physical and mental health, and health care utilization [222]

By suppressing appetite, they aid individuals in consuming fewer calories without heightened effort